Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLLByTatyana Feldman, MD December 15th 2023Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.